title: The use of low-dose alemtuzumab in pretreated B-cell chronic lymphocytic leukemia.
authors.forename: M
authors.initials: M
authors.lastname: Tarnani
authors.forename: G
authors.initials: G
authors.lastname: D'Arena
authors.forename: D G
authors.initials: DG
authors.lastname: Efremov
authors.forename: S
authors.initials: S
authors.lastname: Marietti
authors.forename: Sica
authors.initials: S
authors.lastname: S
authors.forename: G
authors.initials: G
authors.lastname: Leone
authors.forename: L
authors.initials: L
authors.lastname: Laurenti
mesh_terms: D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab